Adelaide Research & Scholarship: Search

Search

Results 21-30 of 97 (Search time: 0.005 seconds).

previous
1
2
3
4
5
6
...
10
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2020	Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission	Pagani, I.S.; Dang, P.; Saunders, V.A.; Grose, R.; Shanmuganathan, N.; Kok, C.H.; Carne, L.; Rwodzi, Z.; Watts, S.; McLean, J.; Braley, J.; Altamura, H.; Yeung, D.T.; Branford, S.; Yong, A.S.M.; White, D.L.; Hughes, T.P.; Ross, D.M.
	2020	Widespread aberrant alternative splicing despite molecular remission in chronic myeloid leukaemia patients	Schmitz, U.; Shah, J.S.; Dhungel, B.P.; Monteuuis, G.; Luu, P.-L.; Petrova, V.; Metierre, C.; Nair, S.S.; Bailey, C.G.; Saunders, V.A.; Turhan, A.G.; White, D.L.; Branford, S.; Clark, S.J.; Hughes, T.P.; Wong, J.J.-L.; Rasko, J.E.J.
	2020	Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?	Branford, S.
	2014	Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline	Branford, S.; Yeung, D.; Parker, W.; Roberts, N.; Purins, L.; Braley, J.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Donaldson, Z.; Leong, M.; Fletcher, L.; Seymour, J.; Grigg, A.; Ross, D.; Hughes, T.
	2014	Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination	Parker, W.; Phillis, S.; Yeung, D.; Hughes, T.; Scott, H.; Branford, S.
	2014	Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib	Hughes, T.; Lipton, J.; Spector, N.; Cervantes, F.; Pasquini, R.; Clementino, N.; Dorlhiac Llacer, P.; Schwarer, A.; Mahon, F.; Rea, D.; Branford, S.; Purkayastha, D.; Collins, L.; Szczudlo, T.; Leber, B.
	2022	Measurable residual disease in chronic myeloid leukemia.	Branford, S.; Apperley, J.F.
	2019	Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia	Ross, D.M.; Pagani, I.S.; Irani, Y.D.; Clarson, J.; Leclercq, T.; Dang, P.; McLean, J.; Saunders, V.A.; Carne, L.; Reynolds, J.; Ritchie, D.S.; White, D.L.; Branford, S.; Hughes, T.P.; Yong, A.S.M.
	2021	Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia	Shanmuganathan, N.; Pagani, I.S.; Ross, D.M.; Park, S.; Yong, A.S.; Braley, J.A.; Altamura, H.K.; Hiwase, D.K.; Yeung, D.T.; Kim, D.-W.; Branford, S.; Hughes, T.P.
	2021	RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses	Adnan Awad, S.; Dufva, O.; Ianevski, A.; Ghimire, B.; Koski, J.; Maliniemi, P.; Thomson, D.; Schreiber, A.; Heckman, C.A.; Koskenvesa, P.; Korhonen, M.; Porkka, K.; Branford, S.; Aittokallio, T.; Kankainen, M.; Mustjoki, S.